Top

Published in:

01-06-2013 | Case Report

Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate

Authors: Yoo Jin Lee, Joon Ho Moon, Ho Cheol Shin, Jong Won Seo, Seo Ae Han, Sang Kyeong Seo, Sang Kyun Sohn

Published in: International Journal of Hematology | Issue 6/2013

Abstract

The present report describes two chronic myelogenous leukemia (CML) patients with the JAK2-V617F mutation who were in complete hematologic and cytogenetic remission and subsequently developed clinical features of essential thrombocythemia under treatment with tyrosine kinase inhibitors. In light of the findings from previous reports, screening for the JAK2-V617F mutation should be considered for any Ph⁺ CML patients with thrombocytosis, leukocytosis, or erythrocytosis at diagnosis and for patients who subsequently develop thrombocytosis, leukocytosis, or erythrocytosis during follow-up, even for CML patients in complete cytogenetic response and major molecular response.

Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R, et al. Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia. Leukemia. 2011;25(3):463–72.PubMedCrossRef

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMed

Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S, et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood. 2005;106:2920–1.PubMedCrossRef

Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, et al. Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia. 2008;22(5):1059–62.PubMedCrossRef

Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, et al. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia. 2007;21(5):1103–4.PubMed

Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G, et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood. 2007;109(9):4106–7.PubMedCrossRef

Jallades L, Hayette S, Tigaud I, Johnston A, Coiffier B, Magaud JP, et al. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis. Leuk Res. 2008;32(10):1608–10.PubMedCrossRef

Bornhauser M, Mohr B, Oelschlaegel U, Bornhäuser P, Jacki S, Ehninger G, et al. Concurrent JAK2 (V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia. 2007;21:1824–6.PubMedCrossRef

Busche G, Hussein K, Bock O, Kreipe H. Insights into JAK2-V617F mutation in CML. Lancet Oncol. 2007;8:863–4.PubMedCrossRef

10.

Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, et al. JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia. 2008;22(7):1454–5.PubMedCrossRef

11.

Cappetta M, Pérez V, Zubillaga MN, Elizondo V, Manrique G, Prosper I, et al. Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis. Int J Lab Hematol. 2013;35(1):e4–5.PubMedCrossRef

12.

Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, et al. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms. Diagn Mol Pathol. 2012;21(3):176–83.PubMedCrossRef

13.

Xiao X, Zhang Y, Zhang GS, Zheng WL, Xiao L, Liu SF. Coexistence of JAK2V617F mutation and BCR-ABL1 transcript in two Chinese patients with chronic myelogenous leukemia. Acta Haematol. 2012;127(1):47–9.PubMedCrossRef

14.

Toogeh G, Ferdowsi S, Naadali F, Alimoghaddam K, Ghavamzadeh A, Shirkoohi R, et al. Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera. Med Oncol. 2011;28(4):1555–8.PubMedCrossRef

15.

Tefferi A, Levitt R, Lasho TL, Knudson RA, Ketterling RP. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia. Eur J Haematol. 2010;85(1):86–7.PubMed

16.

Caocci G, Atzeni S, Orrù N, Littera R, Culurgioni F, Marongiu F, et al. Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation. Leuk Res. 2010;34(1):e27–9.PubMedCrossRef

17.

Pardini S, Fozza C, Contini S, Rimini E, Ottaviani E, Amabile M, et al. A case of coexistence between JAK2V617F and BCR/ABL. Eur J Haematol. 2008;81(1):75–6.PubMedCrossRef

18.

Kim YK, Shin MG, Kim HR, Yang DH, Cho SH, Lee JJ, et al. Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders. Leuk Res. 2008;32(6):993–5.PubMedCrossRef

19.

Kramer A, Reiter A, Kruth J, Erben P, Hochhaus A, Müller M, et al. JAK2–V617F mutation in a patient with Philadelphia chromosome-positive chronic myeloid leukaemia. Lancet Oncol. 2007;8:658–60.PubMedCrossRef

20.

Lisa P, Ambra S, Barbara S, Umberto O, Silvia B, Alberto B, et al. Concomitant occurrence of BCR-ABL and JAK2-V617F mutation. Blood. 2011;118:3445–6.CrossRef

21.

Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet. 1996;89(1):74–6.PubMedCrossRef

22.

Stoll DB, Peterson P, Exten R, Laszlo J, Pisciotta AV, Ellis JT, et al. Clinical presentation and natural history of patients with essential thrombocythemia and the Philadelphia chromosome. Am J Hematol. 1988;27(2):77–83.PubMedCrossRef

Title: Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate
Authors: Yoo Jin Lee
Joon Ho Moon
Ho Cheol Shin
Jong Won Seo
Seo Ae Han
Sang Kyeong Seo
Sang Kyun Sohn
Publication date: 01-06-2013
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 6/2013
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-013-1326-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2013

All that glitters is not gold: differential diagnosis of clover-leaf lymphocytes

Eosinophilic “candy floss”-like inclusions in myeloma cells

Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry

Genotypic and phenotypic features of Japanese patients with mild to moderate hemophilia A

Treatment of gastric MALT lymphoma with a focus on Helicobacter pylori eradication

Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer